<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077623</url>
  </required_header>
  <id_info>
    <org_study_id>BA16740</org_study_id>
    <nct_id>NCT00077623</nct_id>
  </id_info>
  <brief_title>A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.</brief_title>
  <official_title>A Randomized, Controlled, Open-Label, Multi- Center, Parallel-Group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Subcutaneously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of subcutaneous (sc) Mircera given as
      maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who
      were previously receiving sc epoetin. The anticipated time on study treatment is 1-2 years
      and the target sample size is 100-500 individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Hemoglobin Concentration From Baseline to Evaluation Periods</measure>
    <time_frame>Baseline (Week -4 to Week -1) and Evaluation period (Week 29 to Week 36)</time_frame>
    <description>A time adjusted mean change in hemoglobin (Hb) concentration was calculated using an area under the curve (AUC) approach, for both periods separately. Change in Hb concentration between the baseline and evaluation periods was calculated by subtracting the calculated average baseline Hb value from the average evaluation period Hb value. All blood samples for Hb measurements were taken prior to study drug administration. Analysis used last observation carried forward (LOCF) for missing Hb values to correct for the impact of early dropouts. The baseline period is defined as Week -4 to Week -1. The evaluation period is defined as Week 29 to Week 36.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Maintaining Average Hb Concentration During the Evaluation Period Within +-1 g/dL of Their Average Baseline Hb Concentration</measure>
    <time_frame>Evaluation period (Week 29 to Week 36)</time_frame>
    <description>All mean Hb values recorded during the evaluation period were calculated and subtracted from the mean baseline Hb value for each participant. The number of participants maintaining their average Hb within +/- 1 g/dL of their average baseline hemoglobin concentration is given. The evaluation period is defined as Week 29 to Week 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Red Blood Cell Transfusions</measure>
    <time_frame>Up to Week 36</time_frame>
    <description>The number of participants who received RBC transfusions were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Events, Any Serious Adverse Events, and Deaths</measure>
    <time_frame>Up to week 52</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Laboratory Abnormalities</measure>
    <time_frame>Up to week 52</time_frame>
    <description>A marked abnormality range was defined as above and/or below a value which was considered to be potentially clinically relevant. Marked laboratory abnormalities were analyzed according to the Roche specified limits for the reference range of the following laboratory parameters: White blood cells (WBC) (3.0- 18.0 10^9/L), platelets (100 - 550 10^9/L), alanine aminotransferase (ALAT) (0 - 110 units per liter [U/L]), alkaline phosphatase (ALP [0 - 220 U/L]), aspartate aminotransferase (ASAT) (0 - 80 U/L), albumin &gt;= 30 g/L, phosphate (0.75 - 1.60 millimoles per liter [mmol/L]), potassium (2.9 - 5.8 mmol/L), glucose (2.80 - 11.10 mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic and Diastolic Blood Pressure - at Weeks 36 and 52 in Hemodialysis Participants</measure>
    <time_frame>From Baseline (Week -4 to Week -1) to Week 36 and Week 52</time_frame>
    <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in sitting position before and after dialysis session in haemodialysis participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Rate at Weeks 36 and 52 in Hemodialysis Participants</measure>
    <time_frame>From Baseline (Week -4 to Week -1) to Week 36 and Week 52</time_frame>
    <description>Pulse rate in beats per minute (BpM) was measured at each study visit, i.e., once a week during the dose titration and evaluation periods, once every two weeks during the long-term safety observation period and at the final visit. It was measured before blood sampling and RO0503821/epoetin administration and before the dialysis session in haemodialysis participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic and Diastolic Blood Pressure at Weeks 36 and 52 in Peritoneal Dialysis Participants</measure>
    <time_frame>From Baseline (Week -4 to Week -1) to Week 36 and Week 52</time_frame>
    <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in sitting position before and after dialysis session in peritoneal dialysis participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Rate - Peritoneal Dialysis Participants</measure>
    <time_frame>From Baseline (Week -4 to Week -1) to Week 36 and Week 52</time_frame>
    <description>Pulse rate in BpM was measured at each study visit, i.e., once a week during the dose titration and evaluation periods, once every two weeks during the long-term safety observation period and at the final visit. It was measured before blood sampling and RO0503821/epoetin administration and before the dialysis session in peritoneal dialysis participants.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">572</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>RO0503821 (1x/2 Weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 microgram (mcg) which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 international units (IU)/week, administered during the week preceding the switch to the study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO0503821 (1x/4 Weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week administered during the week preceding the switch to the study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epoetin Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoetin alfa or beta</intervention_name>
    <description>iv 3 times weekly, as prescribed</description>
    <arm_group_label>Epoetin Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methoxy polyethylene glycol-epoetin beta (Mircera)</intervention_name>
    <description>60, 100 or 180 micrograms sc (starting dose) every 2 weeks</description>
    <arm_group_label>RO0503821 (1x/2 Weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methoxy polyethylene glycol-epoetin beta (Mircera)</intervention_name>
    <description>60, 100 or 180 micrograms sc (starting dose) every 4 weeks</description>
    <arm_group_label>RO0503821 (1x/4 Weeks)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients &gt;=18 years of age;

          -  chronic renal anemia;

          -  on dialysis therapy for at least 12 weeks before screening;

          -  receiving sc epoetin for at least 8 weeks before screening.

        Exclusion Criteria:

          -  women who are pregnant, breastfeeding or using unreliable birth control methods;

          -  administration of another investigational drug within 4 weeks before screening, or
             during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816-5119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95116-1906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2689</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn Center</city>
        <state>Minnesota</state>
        <zip>55430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-salem</city>
        <state>North Carolina</state>
        <zip>27157-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <zip>81050-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>03065-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>04039-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plzen</city>
        <zip>304 60</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>HUS</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bayonne</city>
        <zip>64115</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boulogne</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cabestany</city>
        <zip>66330</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pantin</city>
        <zip>93500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-germain-en-laye</city>
        <zip>78100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Priest En Jarez</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thionville</city>
        <zip>57126</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Hersfeld</city>
        <zip>36251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12045</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mestre</city>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prato</city>
        <zip>50047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Venezia</city>
        <zip>30122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cuernavaca</city>
        <zip>62448</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama City</city>
        <zip>0</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kielce</city>
        <zip>25-736</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>50-417</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <zip>00732</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alcorcon</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huddinge</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlstad</city>
        <zip>65185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10310</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phitsanulok</city>
        <zip>65000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <zip>BT9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leicester</city>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE22 8PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2004</study_first_posted>
  <results_first_submitted>March 24, 2016</results_first_submitted>
  <results_first_submitted_qc>March 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 26, 2016</results_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 817 participants were enrolled in this study conducted from 03 March 2004 to 23 September 2005 at 92 centers worldwide.</recruitment_details>
      <pre_assignment_details>A total of 572 participants were randomized, of which 1 participant did not received the study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RO0503821 (1x/2 Weeks)</title>
          <description>Eligible participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 microgram (mcg) which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 international units per week (IU/week), administered during the week preceding the switch to the study drug.</description>
        </group>
        <group group_id="P2">
          <title>RO0503821 (1x/4 Weeks)</title>
          <description>Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week administered during the week preceding the switch to the study drug.</description>
        </group>
        <group group_id="P3">
          <title>Epoetin Reference</title>
          <description>Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="191"/>
                <participants group_id="P3" count="191"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="148"/>
                <participants group_id="P3" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other-Non safety reason</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient therapeutic response</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis was done on safety population which included all participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>RO0503821 (1x/2 Weeks)</title>
          <description>Eligible participants received RO0503821 subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 mcg which was based on the Epoetin dose of&lt;8000, 8000-16000,or &gt;16000 International units [IU]/Week, administered during the week preceding the switch to the study drug.</description>
        </group>
        <group group_id="B2">
          <title>RO0503821 (1x/4 Weeks)</title>
          <description>Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the Epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/Week administered during the week preceding the switch to the study drug.</description>
        </group>
        <group group_id="B3">
          <title>Epoetin Reference</title>
          <description>Eligible participants received their ongoing weekly subcutaneous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="190"/>
            <count group_id="B2" value="190"/>
            <count group_id="B3" value="191"/>
            <count group_id="B4" value="571"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" spread="15.40"/>
                    <measurement group_id="B2" value="62.5" spread="15.16"/>
                    <measurement group_id="B3" value="60.4" spread="14.70"/>
                    <measurement group_id="B4" value="61.1" spread="15.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Hemoglobin Concentration From Baseline to Evaluation Periods</title>
        <description>A time adjusted mean change in hemoglobin (Hb) concentration was calculated using an area under the curve (AUC) approach, for both periods separately. Change in Hb concentration between the baseline and evaluation periods was calculated by subtracting the calculated average baseline Hb value from the average evaluation period Hb value. All blood samples for Hb measurements were taken prior to study drug administration. Analysis used last observation carried forward (LOCF) for missing Hb values to correct for the impact of early dropouts. The baseline period is defined as Week -4 to Week -1. The evaluation period is defined as Week 29 to Week 36.</description>
        <time_frame>Baseline (Week -4 to Week -1) and Evaluation period (Week 29 to Week 36)</time_frame>
        <population>The Per Protocol population included all randomized participants except those not meeting inclusion criterion related to stable baseline Hb values, inadequate iron status, hemoglobinopathies/hemolysis, RBC transfusion/blood loss, with &lt;5 recorded Hb values during the evaluation period, with missing administrations of the study drug/ reference drug</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week, administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Reference</title>
            <description>Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Hemoglobin Concentration From Baseline to Evaluation Periods</title>
          <description>A time adjusted mean change in hemoglobin (Hb) concentration was calculated using an area under the curve (AUC) approach, for both periods separately. Change in Hb concentration between the baseline and evaluation periods was calculated by subtracting the calculated average baseline Hb value from the average evaluation period Hb value. All blood samples for Hb measurements were taken prior to study drug administration. Analysis used last observation carried forward (LOCF) for missing Hb values to correct for the impact of early dropouts. The baseline period is defined as Week -4 to Week -1. The evaluation period is defined as Week 29 to Week 36.</description>
          <population>The Per Protocol population included all randomized participants except those not meeting inclusion criterion related to stable baseline Hb values, inadequate iron status, hemoglobinopathies/hemolysis, RBC transfusion/blood loss, with &lt;5 recorded Hb values during the evaluation period, with missing administrations of the study drug/ reference drug</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.96"/>
                    <measurement group_id="O2" value="-0.11" spread="0.97"/>
                    <measurement group_id="O3" value="-0.12" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The non-inferiority test for treatment differences in Hb change from baseline, based on ANCOVA analysis with a non-inferiority limit of -0.75 g/dL (Per Protocol Population)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The two RO0503821 dosing schedules were compared separately to epoetin reference using ANCOVA, with Hb at BL and region as the covariates. The test for non-inferiority were based on the lower limit of the two-sided 97.5% confidence interval for the difference between the two groups. When the lower limit was greater than or equal to –0.75 g/dL, the RO0503821 groups were regarded as non-inferior to the epoetin reference group. The confidence level of 97.5% was chosen to adjust for multiplicity.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value for the non-inferiority test can be derived via the t-test.</p_value_desc>
            <method>ANCOVA, CI for difference between groups</method>
            <param_type>Mean Difference between groups</param_type>
            <param_value>0.141</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.098</ci_lower_limit>
            <ci_upper_limit>0.380</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The non-inferiority test for treatment differences in Hb change from baseline, based on ANCOVA analysis with a non-inferiority limit of -0.75 g/dL (Per Protocol Population)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The two RO0503821 dosing schedules were compared separately to epoetin reference using ANCOVA, with Hb at BL and region as the covariates. The test for non-inferiority were based on the lower limit of the two-sided 97.5% confidence interval for the difference between the two groups. When the lower limit was greater than or equal to –0.75 g/dL, the RO0503821 groups were regarded as non-inferior to the epoetin reference group. The confidence level of 97.5% was chosen to adjust for multiplicity .</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value for the non-inferiority test can be derived via the t-test.</p_value_desc>
            <method>ANCOVA, CI for difference between groups</method>
            <param_type>Mean Difference between groups</param_type>
            <param_value>-0.022</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.262</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Maintaining Average Hb Concentration During the Evaluation Period Within +-1 g/dL of Their Average Baseline Hb Concentration</title>
        <description>All mean Hb values recorded during the evaluation period were calculated and subtracted from the mean baseline Hb value for each participant. The number of participants maintaining their average Hb within +/- 1 g/dL of their average baseline hemoglobin concentration is given. The evaluation period is defined as Week 29 to Week 36.</description>
        <time_frame>Evaluation period (Week 29 to Week 36)</time_frame>
        <population>The Intent-to-Treat (ITT) population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week, administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Reference</title>
            <description>Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Maintaining Average Hb Concentration During the Evaluation Period Within +-1 g/dL of Their Average Baseline Hb Concentration</title>
          <description>All mean Hb values recorded during the evaluation period were calculated and subtracted from the mean baseline Hb value for each participant. The number of participants maintaining their average Hb within +/- 1 g/dL of their average baseline hemoglobin concentration is given. The evaluation period is defined as Week 29 to Week 36.</description>
          <population>The Intent-to-Treat (ITT) population included all randomized participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Red Blood Cell Transfusions</title>
        <description>The number of participants who received RBC transfusions were reported.</description>
        <time_frame>Up to Week 36</time_frame>
        <population>Safety population included all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week, administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Reference</title>
            <description>Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Red Blood Cell Transfusions</title>
          <description>The number of participants who received RBC transfusions were reported.</description>
          <population>Safety population included all participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Events, Any Serious Adverse Events, and Deaths</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>Up to week 52</time_frame>
        <population>Safety population included all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week, administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Reference</title>
            <description>Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Events, Any Serious Adverse Events, and Deaths</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>Safety population included all participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE's</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="177"/>
                    <measurement group_id="O3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE's</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Marked Laboratory Abnormalities</title>
        <description>A marked abnormality range was defined as above and/or below a value which was considered to be potentially clinically relevant. Marked laboratory abnormalities were analyzed according to the Roche specified limits for the reference range of the following laboratory parameters: White blood cells (WBC) (3.0– 18.0 10^9/L), platelets (100 – 550 10^9/L), alanine aminotransferase (ALAT) (0 – 110 units per liter [U/L]), alkaline phosphatase (ALP [0 – 220 U/L]), aspartate aminotransferase (ASAT) (0 – 80 U/L), albumin &gt;= 30 g/L, phosphate (0.75 - 1.60 millimoles per liter [mmol/L]), potassium (2.9 – 5.8 mmol/L), glucose (2.80 – 11.10 mmol/L).</description>
        <time_frame>Up to week 52</time_frame>
        <population>Safety population included all participants who received at least one dose of study drug. Maximum number of participants available at the time of assessment were denoted as ‘n'.</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week, administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Reference</title>
            <description>Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marked Laboratory Abnormalities</title>
          <description>A marked abnormality range was defined as above and/or below a value which was considered to be potentially clinically relevant. Marked laboratory abnormalities were analyzed according to the Roche specified limits for the reference range of the following laboratory parameters: White blood cells (WBC) (3.0– 18.0 10^9/L), platelets (100 – 550 10^9/L), alanine aminotransferase (ALAT) (0 – 110 units per liter [U/L]), alkaline phosphatase (ALP [0 – 220 U/L]), aspartate aminotransferase (ASAT) (0 – 80 U/L), albumin &gt;= 30 g/L, phosphate (0.75 - 1.60 millimoles per liter [mmol/L]), potassium (2.9 – 5.8 mmol/L), glucose (2.80 – 11.10 mmol/L).</description>
          <population>Safety population included all participants who received at least one dose of study drug. Maximum number of participants available at the time of assessment were denoted as ‘n'.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Platelets, high; n=189,189, 188</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, low; n=189,189, 188</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, high; n = 118, 112, 115</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, low; n = 118, 112, 115</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, high; n=189,189, 188</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, low; n=189,189, 188</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT, high; n=189,189, 188</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, high; n=189,189, 188</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT, high; n=185,189, 186</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, low; n=182,186, 185</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate, high; n=189,189, 188</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate, low; n=189,189, 188</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, high; n=189,189, 188</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, low; n=189,189, 188</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose fasting, high; n=126,137, 124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose fasting, low; n=126,137, 124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic and Diastolic Blood Pressure - at Weeks 36 and 52 in Hemodialysis Participants</title>
        <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in sitting position before and after dialysis session in haemodialysis participants.</description>
        <time_frame>From Baseline (Week -4 to Week -1) to Week 36 and Week 52</time_frame>
        <population>Safety population included all participants who received at least one dose of study drug. Maximum number of participants available at the time of assessment was denoted as ‘n’.</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week, administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Reference</title>
            <description>Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic and Diastolic Blood Pressure - at Weeks 36 and 52 in Hemodialysis Participants</title>
          <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in sitting position before and after dialysis session in haemodialysis participants.</description>
          <population>Safety population included all participants who received at least one dose of study drug. Maximum number of participants available at the time of assessment was denoted as ‘n’.</population>
          <units>mmHG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP- before dialysis (Week 36, n=150,153, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="12.2"/>
                    <measurement group_id="O2" value="0" spread="15.5"/>
                    <measurement group_id="O3" value="1" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP- before dialysis (Week 52, n= 143, 136, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="13.8"/>
                    <measurement group_id="O2" value="-1" spread="11.1"/>
                    <measurement group_id="O3" value="2" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP - After dialysis (Week 36, n=150, 150, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="13.2"/>
                    <measurement group_id="O2" value="-0" spread="17.3"/>
                    <measurement group_id="O3" value="-1" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP - After dialysis (Week 52, n= 141, 136, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="15"/>
                    <measurement group_id="O2" value="0" spread="14.9"/>
                    <measurement group_id="O3" value="2" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP - before dialysis(Week 36, n=150, 153, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="22.1"/>
                    <measurement group_id="O2" value="4" spread="26.1"/>
                    <measurement group_id="O3" value="-1" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP - before dialysis(Week 52, n=143, 136,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="25.2"/>
                    <measurement group_id="O2" value="3" spread="23.1"/>
                    <measurement group_id="O3" value="1" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP - After dialysis (Week 36, n=150, 152, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="24.4"/>
                    <measurement group_id="O2" value="-0" spread="27.1"/>
                    <measurement group_id="O3" value="-2" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP - After dialysis (Week 52, n=141, 136, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24.1"/>
                    <measurement group_id="O2" value="-2" spread="23.4"/>
                    <measurement group_id="O3" value="2" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse Rate at Weeks 36 and 52 in Hemodialysis Participants</title>
        <description>Pulse rate in beats per minute (BpM) was measured at each study visit, i.e., once a week during the dose titration and evaluation periods, once every two weeks during the long-term safety observation period and at the final visit. It was measured before blood sampling and RO0503821/epoetin administration and before the dialysis session in haemodialysis participants.</description>
        <time_frame>From Baseline (Week -4 to Week -1) to Week 36 and Week 52</time_frame>
        <population>Safety population included all participants who received at least one dose of study drug. Maximum number of participants available at the time of assessment was denoted as ‘n’.</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week, administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Reference</title>
            <description>Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate at Weeks 36 and 52 in Hemodialysis Participants</title>
          <description>Pulse rate in beats per minute (BpM) was measured at each study visit, i.e., once a week during the dose titration and evaluation periods, once every two weeks during the long-term safety observation period and at the final visit. It was measured before blood sampling and RO0503821/epoetin administration and before the dialysis session in haemodialysis participants.</description>
          <population>Safety population included all participants who received at least one dose of study drug. Maximum number of participants available at the time of assessment was denoted as ‘n’.</population>
          <units>BpM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulse rate (Week 36, n=147,149, 156 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0" spread="11.8"/>
                    <measurement group_id="O2" value="1" spread="11.3"/>
                    <measurement group_id="O3" value="-0" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse rate (Week 52, n= 140, 135, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0" spread="10.6"/>
                    <measurement group_id="O2" value="1" spread="12.5"/>
                    <measurement group_id="O3" value="-0" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic and Diastolic Blood Pressure at Weeks 36 and 52 in Peritoneal Dialysis Participants</title>
        <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in sitting position before and after dialysis session in peritoneal dialysis participants.</description>
        <time_frame>From Baseline (Week -4 to Week -1) to Week 36 and Week 52</time_frame>
        <population>Safety population included all participants who received at least one dose of study medication. Maximum number of participants available at the time of assessment were analysed and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week, administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Reference</title>
            <description>Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic and Diastolic Blood Pressure at Weeks 36 and 52 in Peritoneal Dialysis Participants</title>
          <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in sitting position before and after dialysis session in peritoneal dialysis participants.</description>
          <population>Safety population included all participants who received at least one dose of study medication. Maximum number of participants available at the time of assessment were analysed and reported.</population>
          <units>mm HG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP (Week 36, n=7,10,12 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="12.8"/>
                    <measurement group_id="O2" value="-7" spread="13.9"/>
                    <measurement group_id="O3" value="2" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP (Week 52, n= 8, 9, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="10.3"/>
                    <measurement group_id="O2" value="-8" spread="18.7"/>
                    <measurement group_id="O3" value="2" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP - (Week 36, n=7, 10, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="26.7"/>
                    <measurement group_id="O2" value="-20" spread="33.5"/>
                    <measurement group_id="O3" value="7" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP - (Week 52, n=8, 9,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="22.1"/>
                    <measurement group_id="O2" value="-20" spread="36.9"/>
                    <measurement group_id="O3" value="12" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse Rate - Peritoneal Dialysis Participants</title>
        <description>Pulse rate in BpM was measured at each study visit, i.e., once a week during the dose titration and evaluation periods, once every two weeks during the long-term safety observation period and at the final visit. It was measured before blood sampling and RO0503821/epoetin administration and before the dialysis session in peritoneal dialysis participants.</description>
        <time_frame>From Baseline (Week -4 to Week -1) to Week 36 and Week 52</time_frame>
        <population>Safety population included all participants who received at least one dose of study drug. Maximum number of participants available at the time of assessment was denoted as ‘n’.</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week, administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Reference</title>
            <description>Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate - Peritoneal Dialysis Participants</title>
          <description>Pulse rate in BpM was measured at each study visit, i.e., once a week during the dose titration and evaluation periods, once every two weeks during the long-term safety observation period and at the final visit. It was measured before blood sampling and RO0503821/epoetin administration and before the dialysis session in peritoneal dialysis participants.</description>
          <population>Safety population included all participants who received at least one dose of study drug. Maximum number of participants available at the time of assessment was denoted as ‘n’.</population>
          <units>BpM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulse rate (Week 36, n=147,149, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="16.7"/>
                    <measurement group_id="O2" value="4" spread="12.2"/>
                    <measurement group_id="O3" value="6" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse rate (Week 52, n= 140, 135, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="12.7"/>
                    <measurement group_id="O2" value="1" spread="7.8"/>
                    <measurement group_id="O3" value="2" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 52</time_frame>
      <desc>Serious adverse events and non-serious adverse events are reported in safety analysis set, which consists of all participants who received at least one dose of study drug and had a safety assessment performed post baseline.</desc>
      <group_list>
        <group group_id="E1">
          <title>RO0503821 (1x/2 Weeks)</title>
          <description>Eligible participants received RO0503821 subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week, administered during the week preceding the switch to the study drug.</description>
        </group>
        <group group_id="E2">
          <title>RO0503821 (1x/4 Weeks)</title>
          <description>Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of&lt;8000, 8000-16000, or &gt;16000 IU/week administered during the week preceding the switch to the study drug.</description>
        </group>
        <group group_id="E3">
          <title>Epoetin Reference</title>
          <description>Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Anaemia vitamin b12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Aplasia pure red cell</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Coronary artery atherosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal cortical insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Bezoar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Duodenitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Peritoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Thrombosis mesenteric vessel</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Ischaemic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Staphylococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Bronchitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Catheter Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cellulitis gangrenous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hepatitis c</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Herpes ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Intestinal gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pneumonia chlamydial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Serratia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Vascular bypass dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Thyroid gland cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Toxic induced encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Brain stem haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cerebral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hypoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cognitive deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Bladder cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Bladder tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pyelectasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cervix disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Penile necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Leukocytoclastic vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Atherosclerosis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Atherosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Peripheral occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="111" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Procedural hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roche Trial Information Hotline</name_or_title>
      <organization>F. Hoffmann-La Roche AG</organization>
      <phone>+41 616878333</phone>
      <email>global.trial_information@roche.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

